EUCTR2013-002740-85-ES进行中（未招募）1 期
A Pilot Randomized, Double-blind, Placebo-controlled Clinical Trial to Obtain Preliminary Data on Efficacy and Safety in the Application of PRGF-Endoret by Mesotherapy, in the Treatment of Male and Female Androgenetic Alopecia of Over 6 Months Duration. - Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia
BTI BIOTECHNOLOGY INSTITUTE IMASD0 个研究点目标入组 24 人开始时间: 2013年11月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •* Androgenetic alopecia according to the following scales:
- •Men: Hamilton/Norwood Scale: grades II-VI
- •Women: Ludwig Scale grades I-II.
- •* Possibility of follow-up during the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 24
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •?No androgenetic alopecia
- •?Telogen and anagen effluvium
- •?Active inflammation or infection in the intervention area
- •?Presence of active systemic infections.
- •?Background of cancerous or precancerous lesions.
- •?Background of connective or rheumatic diseases.
- •?Suffering from any serious blood disorders.
- •?To have undergone treatments for alopecia in the previous 6 months.
- •?Previous hair implants
- •?Intake of drugs that affect hair loss.
- •?Be undergoing immunosuppressive therapy and/or anticoagulants.
- •?Known intolerance to mesotherapy.
- •?Taking contraceptives containing cyproterone acetate.
- •?In general, any limitations that would prevent the proper application of both treatments and the right monitoring of the efficacy variables.
研究者
相似试验
已完成
Unknown
A pilot randomized, double-blind, placebo-controlled, parallel-group clinical study to study the safety and tolerability of IP in healthy adultsCTRI/2023/03/050853Vedic Lifesciences Pvt Ltd64
进行中（未招募）
1 期
Efficacy and safety study for Fluticasone Furoate Nasal Spray in adults and adolescents with non-allergic rhinitis.Irritant (non-allergic) rhinitisEUCTR2015-004888-37-Outside-EU/EEAGlaxoSmithKline Research and Development Ltd102
进行中（未招募）
不适用
A pilot, randomized, double-blind, placebo-controlled, parallel group, multicentre, phase IIa study to determine the clinical safety/tolerability and exploratory efficacy of EHT 0202 (40 and 80 mg bid) as adjunctive therapy to acetylcholinesterase inhibitor over a 3-month period in ambulatory patients suffering from mild to moderate Alzheimer’s Disease (EHT 0202/002 protocol).EUCTR2007-005549-39-FREXONHIT
进行中（未招募）
不适用
A pilot, randomized, double-blind, placebo-controlled, crossoverstudy evaluating the efficacy and safety of Vardenafil versusplacebo administered 12, 18 and 24 hours prior to initiation ofsexual intercourse in subjects with ED.ERECTILE DISFUNCTIONMedDRA version: 6.1Level: PTClassification code 10061461EUCTR2004-001549-13-ITGLAXO SMITHKLINE314
进行中（未招募）
1 期
Study to define the optimal dose, to evaluate efficacy, safety and tolerability of self- administered subcutaneous diclofenac sodium 25-50-75mg/1ml in the treatment of an acute migraine attack with headache.Acute migraine attacks with headache.MedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersEUCTR2017-004828-29-ITIBSA INSTITUT BIOCHIMIQUE SA128